Table 2 Ongoing clinical trials with immune checkpoint blockade pembrolizumab and lenvatinib in solid tumors

NCT03609359

29

Advanced Gastric Cancer

2

/

ORR

recruiting

NCT03006887

6

Transitional Cell Carcinoma

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

1b

/

1.AE 2.DLT

active, not recruiting

NCT02501096

329

Tumors involving non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, or melanoma

1b(LEN)/2(PEM)

Salvage therapy

/

1.MTD (phase 1b)

2.ORR 3.DLT

recruiting

NCT03006926

104

Hepatocellular Carcinoma

1b

/

1.AE 2.DLT 3.ORR 4.DOR by Mrecist and RECIST 1.1 based on IIR analysis

recruiting

NCT03797326

180

Advanced Solid Tumors

Triple Negative Breast Cancer

Ovarian Cancer

Gastric Cancer

Colorectal Cancer

Glioblastoma

Biliary Tract Cancers

2

Salvage therapy

dMMR for Colorectal Cancer

1.ORR 2.Percentage of AE 3.Percentage of Discontinue Study Treatment

not yet recruiting

NCT03776136

100

Advanced Melanoma

2

/

ORR

recruiting

NCT03820986

660

Malignant Melanoma

2(PEM)/3(LEN)

first-line

/

1.PFS 2.OS

not yet recruiting

NCT02973997

60

Thyroid Gland Carcinoma

2

metastasis

/

1.CR rate 2.Confirmed response rate

recruiting

NCT03829332

620

Non-small Cell Lung Cancer

3

first-line

PD-L1 ≥ 1%

1.PFS 2.OS

not yet recruiting

NCT03713593

750

Hepatocellular Carcinoma

3

first-line

/

1.PFS 2.OS

recruiting

NCT03517449

780

Endometrial Neoplasms

3

MMR

1.PFS 2.OS

recruiting

NCT03321630

24

GastroEsophageal Cancer

2

salvage therapy

correlative biomarker studies.

1.ORR 2.OS

recruiting

NCT03829319

726

Nonsquamous Non-small Cell Lung Cancer

3

first-line

PD-L1

Part 1: DLT AE Part 2: PFS OS

not yet recruiting

NCT02811861

1050

Renal Cell Carcinoma

3

first-line

/

PFS

recruiting

NCT03516981

192

Advanced Non-Small Cell Lung Cancer

2

Gene expression profile and TMB

ORR

recruiting